References - Neonatal Intensive Care Drug Manual

1. Australian Paediatric Endocrine Group (APEG). Guidelines for management of congenital hypothyroidism. December 2007. Accessed on 29 May 2018.
2. Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab. 2014;99:363-84.
3. Aitken J, Williams FLR. A systematic review of thyroid dysfunction in preterm neonates exposed to topical iodine. Archives of Disease in Childhood: Fetal and Neonatal Edition. 2014;99:F21-F8.
4. l'Allemand D, Gruters A, Beyer P, Weber B. Iodine in contrast agents and skin disinfectants is the major cause for hypothyroidism in premature infants during intensive care. Horm Res. 1987;28:42-9.
5. Smerdely P, Lim A, Boyages SC, Waite K, Wu D, Roberts V, Leslie G, Arnold J, John E, Eastman CJ. Topical iodine-containing antiseptics and neonatal hypothyroidism in very-low-birthweight infants. Lancet. 1989;2:661-4.
6. Endocrine Society of Australia statement on thyroxine preparations available in Australia. https://endocrinesociety.org.au/position-statements.asp.
7. American Academy of P, Rose SR, Section on E, Committee on Genetics ATA, Brown RS, Public Health Committee LWPES, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, Varma SK. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006;117:2290-303.
8. Hashemipour M, Hovsepian S, Ansari A, Keikha M, Khalighinejad P, Niknam N. Screening of congenital hypothyroidism in preterm, low birth weight and very low birth weight neonates: A systematic review. Pediatrics and Neonatology. 2018;59:3-14.
9. Srinivasan R, Harigopal S, Turner S, Cheetham T. Permanent and transient congenital hypothyroidism in preterm infants. Acta Paediatrica, International Journal of Paediatrics.
10. Jones JH, Smith S, Dorrian C, Mason A, Shaikh MG. Permanent congenital hypothyroidism with blood spot thyroid stimulating hormone <10 mU/L. Archives of Disease in Childhood. 2018;103:65-7.
11. Pokrovska T, Jones J, Shaikh MG, Smith S, Donaldson MD. How well does the capillary thyroid-stimulating hormone test for newborn thyroid screening predict the venous free thyroxine level? Arch Dis Child. 2016;101:539-45.
12. McGowan S, Jones J, McMillan D, McLaughlin K, Smith S, Leyland K, Charleton P, Donaldson M, Scottish Down Syndrome Screening G. Screening for hypothyroidism in Down syndrome using the capillary thyroid stimulating hormone method. J Pediatr. 2015;166:1013-7.e2.
13. Mehran L, Khalili D, Yarahmadi S, Amouzegar A, Mojarrad M, Ajang N, Azizi F. Worldwide recall rate in newborn screening programs for congenital hypothyroidism. International Journal of Endocrinology and Metabolism. 2017;15.
14. Mansour C, Ouarezki Y, Jones J, Fitch M, Smith S, Mason A, Donaldson M. Trends in Scottish newborn screening programme for congenital hypothyroidism 1980-2014: strategies for reducing age at notification after initial and repeat sampling. Archives of Disease in Childhood. 2017;102:936-41.
15. Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler G, Espe Pes Slep Jspe Apeg Appes I, Congenital Hypothyroidism Consensus Conference G. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr. 2014;81:80-103.
16. LaFranchi SH. Approach to the diagnosis and treatment of neonatal hypothyroidism. Journal of Clinical Endocrinology and Metabolism. 2011;96:2959-67.
17. UK Newborn Screening Programme Centre (2013) Congenital Hypothyroidism: Initial Clinical Referral Standards and Guidelines. In: A Laboratory Guide to Newborn Screening in the UK for Congenital Hypothyroidism (pp29-35). https://www. gov. uk/government/ publications/ congenital- hypothyroidism- screening- laboratory- handbook.
18. Ng SM, Anand D, Weindling AM. High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. Cochrane Database Syst Rev. 2009:CD006972.
19. Selva KA, Harper A, Downs A, Blasco PA, Lafranchi SH. Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. J Pediatr. 2005;147:775-80.
20. Selva KA, Mandel SH, Rien L, Sesser D, Miyahira R, Skeels M, Nelson JC, Lafranchi SH. Initial treatment dose of L-thyroxine in congenital hypothyroidism. J Pediatr. 2002;141:786-92.
21. Rahmani K, Yarahmadi S, Etemad K, Koosha A, Mehrabi Y, Aghang N, Soori H. Congenital hypothyroidism: Optimal initial dosage and time of initiation of treatment: A systematic review. International Journal of Endocrinology and Metabolism. 2016;14 (3) (no pagination).
22. Rovet JF, Ehrlich RM. Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr. 1995;126:380-6.
23. Osborn DA, Hunt RW. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia. Cochrane Database Syst Rev. 2007:CD005945.
24. Osborn DA, Hunt RW. Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2007:CD005948.
25. Briet JM, van Wassenaer AG, Dekker FW, de Vijlder JJ, van Baar A, Kok JH. Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age. Pediatrics. 2001;107:712-8.
26. van Wassenaer AG, Kok JH, de Vijlder JJ, Briet JM, Smit BJ, Tamminga P, van Baar A, Dekker FW, Vulsma T. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation. N Engl J Med. 1997;336:21-6.
27. van Wassenaer AG, Westera J, Houtzager BA, Kok JH. Ten-year follow-up of children born at <30 weeks' gestational age supplemented with thyroxine in the neonatal period in a randomized, controlled trial. Pediatrics. 2005;116:e613-8.
28. Marchal JP, Maurice-Stam H, Ikelaar NA, Klouwer FCC, Verhorstert KWJ, Witteveen ME, Houtzager BA, Grootenhuis MA, Van Trotsenburg ASP. Effects of early thyroxine treatment on development and growth at age 10.7 years: Follow-up of a randomized placebo-controlled trial in children with Down's syndrome. Journal of Clinical Endocrinology and Metabolism. 2014;99:E2722-E9.
29. Van Trotsenburg ASP, Vulsma T, Rutgers Van Rozenburg-Marres SL, Van Baar AL, Ridder JCD, Heymans HSA, Tijssen JGP, De Vijlder JJM. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old down syndrome children: A randomized clinical trial. Journal of Clinical Endocrinology and Metabolism. 2005;90:3304-11.
30. Talwar S, Bhoje A, Khadagawat R, Chaturvedi P, Sreenivas V, Makhija N, Sahu M, Choudhary SK, Airan B. Oral thyroxin supplementation in infants undergoing cardiac surgery: A double blind placebo controlled randomized clinical trial. Journal of Thoracic and Cardiovascular Surgery. 2018.
31. Virili C, Giovanella L, Fallahi P, Antonelli A, Santaguida MG, Centanni M, Trimboli P. Levothyroxine therapy: Changes of TSH levels by switching patients from tablet to liquid formulation. A systematic review and meta-analysis. Frontiers in Endocrinology. 2018;9 (JAN) (no pagination).
32. Laurent I, Tang S, Astere M, Wang KR, Deng S, Xiao L, Li QF. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine. 2018;61:28-35.
33. Peroni E, Vigone MC, Mora S, Bassi LA, Pozzi C, Passoni A, Weber G. Congenital hypothyroidism treatment in infants: A comparative study between liquid and tablet formulations of levothyroxine. Hormone Research in Paediatrics. 2014;81:50-4.
34. Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. J Clin Endocrinol Metab. 2013;98:610-7.
35. Micromedex. Accessed online on 29 May 2018.
36. MIMS Australia. Eutroxsig and Eltroxin. Accessed on 29 May 2018.
|